Loading…
Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes
Background Prophylactic para-aortic nodal dissection (PAND) has no proven benefits for potentially curable advanced gastric cancer.However,the value of therapeutic PAND for involved para-aortic nodes (PANs) in patients with locally advanced gastric cancers has not been determined yet.Methods Between...
Saved in:
Published in: | Chinese medical journal 2014, Vol.127 (3), p.435-441 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background Prophylactic para-aortic nodal dissection (PAND) has no proven benefits for potentially curable advanced gastric cancer.However,the value of therapeutic PAND for involved para-aortic nodes (PANs) in patients with locally advanced gastric cancers has not been determined yet.Methods Between 1998 and 2010,157 gastric cancer patients with 1-3 involved PANs underwent extended D2 (D2+) lymphadenectomy plus PAND (PAND group,n=69) or extended D2 lymphadenectomy alone (non-PAND group,n=88).The clinicopathologic features and prognostic data were compared between the two groups.A propensity score-adjusted analysis was used for a balanced comparison.Results The rate of PAN metastasis was 40.6% (28/69) in the PAND group.The 5-year survival rate was significantly higher in the PAND group than in the non-PAND group (43.7% vs.31.8%,P=-0.044).Compared to the non-PAND group,the death hazard ratios in the PAND group were 0.45 (95% CI 0.274-0.739; P=0.002) and 0.536 (95% CI 0.328-0.861; P=-0.0097) by multivariate analysis without and with propensity score adjustment respectively.Recurrence rate at 5 years was 39.1% in the PAND group and 43.2% in the non-PAND group (P=0.628).Conclusion Extended D2 lymphadenectomy plus PAND is associated with superior outcomes for advanced gastric cancer patients with 1-3 involved PANs. |
---|---|
ISSN: | 0366-6999 2542-5641 |
DOI: | 10.3760/cma.j.issn.0366-6999.20130664 |